Related Experiment Video

Updated: Mar 6, 2026

Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma
13:18

Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma

Published on: March 3, 2023

1.8K

ErbB Proteins as Molecular Target of Dietary Phytochemicals in Malignant Diseases

Alexandru Filippi1, Oana-Alina Ciolac1, Constanța Ganea1

  • 1Department of Biophysics, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania.

Journal of Oncology
|March 14, 2017
PubMed

Insights

ErbB protein overexpression drives aggressive cancers. Epigallocatechin-3-gallate (EGCG) and curcumin show promise in targeting ErbB signaling pathways, offering new therapeutic avenues for challenging malignancies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Overexpression of ErbB proteins, in normal and mutated forms, correlates with invasive cancers, metastasis, and resistance to apoptosis, complicating treatment.
  • Key downstream signaling pathways affected by ErbB receptors include MAPK, STAT, and PI3K/AKT/mTOR, which mediate cancer cell proliferation and survival.

Purpose of the Study:

  • To review the role of ErbB proteins in cancer development and progression.
  • To examine the anticancer biological activities of epigallocatechin-3-gallate (EGCG) and curcumin against ErbB-expressing malignancies.
  • To discuss challenges and advancements in the bioavailability and administration of EGCG and curcumin.

Main Methods:

  • Literature review focusing on studies investigating ErbB protein involvement in cancer.
  • Analysis of research on the direct and indirect effects of EGCG and curcumin on ErbB expression and downstream signaling.
  • Review of studies addressing bioavailability issues and novel delivery strategies for EGCG and curcumin.

Main Results:

  • ErbB protein overexpression is a significant factor in aggressive cancer phenotypes and treatment resistance.
  • EGCG and curcumin demonstrate direct inhibitory effects on ErbB expression and/or their downstream signaling pathways.
  • Significant progress has been made in overcoming the low oral bioavailability of EGCG and curcumin through innovative formulations and analogs.

Conclusions:

  • ErbB proteins are critical targets in oncology, and their dysregulation contributes to aggressive cancer characteristics.
  • EGCG and curcumin represent promising natural compounds with the potential to modulate ErbB-driven oncogenesis.
  • Further development of formulations and delivery systems is crucial for realizing the full therapeutic potential of EGCG and curcumin in cancer treatment.

More Related Videos

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

2.4K
A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate07:31

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate

Published on: May 3, 2021

4.4K

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.2K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.0K
The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
4.9K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.3K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
4.6K